icon-    folder.gif   Conference Reports for NATAP  
 
  Conference on Retroviruses
and Opportunistic Infections (CROI)
Boston, Massachusetts
March 4-7, 2018
Back grey_arrow_rt.gif
 
 
 
Efficacy and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in virologically-suppressed, treatment-experienced and treatment-naïve women with human immunodeficiency virus type 1
 
 
 
 
Reported by Jules Levin
CROI 2018 March 4-7 Boston, MA
 
Aimee Wilkin1*, Karen Tashima2, Christine Katlama3, Laura Waters4, Ceyhun Bicer5, Donghan Luo6, Eric Y Wong7, Kimberley Brown7
1Wake Forest School of Medicine, Winston-Salem, NC, USA; 2The Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI, USA; 3HIV Clinical Research Unit, Hopital pitie-Salpetriere, Paris, France; 4University College London Hospital, London, UK; 5BICER Consulting & Research, Antwerpen, Belgium; 6Janssen R&D, LLC, Titusville, NJ, USA; 7Janssen Scientific Affairs, LLC, Titusville, NJ, USA

AASDL1

AASDL2

AASDL3

AASDL4

AASDL5

AASDL6

AASDL7

AASDL8

AASDL9